InsightRX Announces the release of InsightRX GEMINI(SM). InsightRX GEMINI℠ is designed to save clinician time and eliminate the need for manual model filteringSAN FRANCISCO, Aug. 27, 2024 -- InsightRX – the leader in Bayesian model-informed precision dosing software – today announced the release of InsightRX GEMINI℠. Privately released to select customers on July 30, 2024, this enhanced dose-selection algorithm for vancomycin was built from datasets of 384,000+ patient treatment courses. Clinical guidelines recommend dosing vancomycin based on area under the plasma drug concentration-time curve (AUC). AUC estimation accuracy is greatly dependent on the model and method used; which has been a time-consuming test and review process

SAN FRANCISCO and FLAGSTAFF, Ariz., June 13, 2024 /PRNewswire/ -- Today, InsightRX and Northern Arizona Healthcare (NAH) announced they will make InsightRX's precision dosing software for heparin therapy available to NAH's pharmacists at Flagstaff Medical Center. NAH expects this deployment to decrease the time it takes to therapeutically dose hospitalized patients with unfractionated heparin to treat and prevent blood clots, improving patient outcomes.Left: Faster anticoagulation attainment by the first measured activated partial thromboplastin time (aPTT) level Right: Sustained duration within a therapeutic anticoagulation range through the first week of therapyNAH is a multi-site, not-for-profit health system that views precision dosing as a transformative approach for advancing medical practice and recognizes InsightRX's continuous learning platform as the solution for clinicians to standardize high-quality care practices."InsightRX was developed to easily integrate into our daily Cerner workflows and individualize heparin therapy with the most advanced methods of patient safety monitoring," said Dr. Scott Waldrop, system director of pharmacy, Northern Arizona Healthcare.InsightRx's integrated heparin dosing platform seamlessly imports patient data from NAH's electronic health records to create a graph of a patient's real-time coagulation status using their current blood draw. This allows clinicians to better identify patients with abnormal bleeding disorders or those at high risk for severe blood clots. Additionally, clinicians can simulate the impact of a recommended heparin dose before verifying the prescription."Anticoagulants have consistently been identified by our providers as a troubling cause of adverse drug events (ADEs) in the inpatient setting. Despite advances in therapeutic heparin dosing and monitoring, determining the right dose continues to be challenging because each patient eliminates heparin at their own rate, based on variables such as their size, blood composition, and underlying disease state," said Dr

CIBC Innovation Banking announced today that it has provided growth financing to InsightRX, a San Francisco-based software company leveraging quantita